Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biden aides tap Google chair for chips research effort, officials say
By Trevor Hunnicutt
WASHINGTON (Reuters) - The Biden administration picked the chairman of Google parent Alphabet, John Hennessy, and four other technology industry experts to help with research-and-development of next generation computer chips, U.S. officials told Reuters.
Hennessy and the selected individuals are set to be announced by the Commerce Department on Tuesday, according to the officials, who declined to be identified. They will be responsible for picking a board of trustees to run the National Semiconductor Technology Center.
That public-private partnership was authorized to lead research on next-generation chips as part of last year's bipartisan $52.7 billion semiconductor manufacturing and research law, which also subsidizes new chip plants. The nonprofit board is expected make politically sensitive decisions, including where in the United States to locate the center's research facilities.
President Joe Biden wants to grow the domestic chipmaking industry to create high-paying jobs, reduce dependence on the major producers in China and Taiwan and to give the United States an edge in the advanced technologies that will power the military technologies of the future.
Economists attribute higher consumer inflation since the COVID-19 pandemic to, among other factors, insufficient chips that sparked shortages in cars, washing machines and video game consoles.
Hennessy, the Google director, is also an electrical engineering and computer science professor at Stanford University.
The selection committee also includes Deloitte Consulting principal Janet Foutty, RAND Corp chief executive Jason Matheny, Anzu Partners venture capitalist and former Qualcomm executive Don Rosenberg and education non-profit president Brenda Wilkerson.
(Reporting by Trevor Hunnicutt; Editing by Cynthia Osterman)
https://finance.yahoo.com/news/biden-aides-tap-google-chair-151730887.html?fr=yhssrp_catchall
Micron is getting hit from all sides:
https://www.bbc.com/news/business-65667746
China bans major chip maker Micron from key infrastructure projects
Excding race! I keyed #3 "Two Phil's on top of my trifecta wager.. He had the lead in the stretch but gave it up at rhe end,
JJ,
Just wanted to thank you for bringing NLST to my attention back in 2018. It's looking to be
the biggestest investment score for me by far.
Again my many thanks for recommending NLST to me...
Mochajet
.
I recall that if NLST were to be up-listed, Chuck would have to deal with
a Board of Directors (BOD). Without contending a bod, He could navigate the legal issues much quicker.
Published on Bloomberg Law's website
https://news.bloomberglaw.com/ip-law/google-fails-to-escape-netlist-suit-over-memory-server-patents
Google Fails to Beat Netlist Suit Over Memory Server Patents
By Matthew Bultman
May 5, 2022, 5:18 PM; Updated: May 5, 2022, 6:42 PM
Netlist Inc. can pursue allegations that Google Inc. memory servers infringe its patented memory module technology, a California federal judge ruled, sending Netlist shares soaring.
Google argued its allegedly infringing memory servers are insulated from infringement claims after Netlist amended parts of the patent during proceedings at the U.S. patent office. Judge Richard Seeborg of the U.S. District Court for the Northern District of California said one of the patent’s claims isn’t subject to that
defense.
The ruling jump-starts a case that dates to 2009. Google said in previous court filings that if Netlist were allowed to pursue infringement of that patent claim, the patent office proceedings “will be rendered meaningless,” and the case will start over with respect to that patent claim.
Netlist shares rose 31% after the ruling. A Google spokesperson declined to comment.
Not Amended
Google asked the patent office in 2010 to reexamine Netlist’s patent. The subsequent proceedings lasted more than a decade, during which Netlist canceled or amended a number of the patent’s claims. It also added dozens of new claims.
After returning to district court in 2021, Netlist amended its infringement contentions.
Google argued it was protected under the “intervening rights” doctrine, which can shield companies from allegations their products infringe patent claims that were added or amended during the reexamination proceedings.
Seeborg found Google had intervening rights for most of Netlist’s patent claims. But there was one Seeborg said wasn’t “amended,” as that term is used in the context of patent prosecution.
While the claim is “technically labeled ‘amended’ in the reexamination certification,” Seeborg said the patent office determined it was “patentable as originally issued.”
The law doesn’t “permit the invocation of intervening rights ‘against claims that the PTO confirmed on reexamination to be patentable as originally issued,’” he wrote.
Seeborg also rejected Google’s argument that Netlist shouldn’t be allowed to allege infringement of the patent claim now, when the claim wasn’t part of the original suit. Seeborg said Netlist couldn’t have sued over the claim in 2009 because the newer, allegedly infringing products came out later.
“The facts of this case therefore do not support a finding that Netlist is engaged in gamesmanship,” Seeborg wrote.
JJ,
Maybe I dreamt it, but I recall NLST management wanting to wait on up listing until all their lawsuits are settled.
MJ
Google Accused of Manipulating Search Results, PriceRunner Suing Company for $2.4 Billion
The Epoch Times
By Naveen Athrappully February 7, 2022
Swedish price comparison company PriceRunner has filed a lawsuit against Google in the Patent and Market Court in Stockholm for a preliminary compensation of 2.1 billion euros ($2.4 billion), accusing Google of showing favoritism toward its own services.
In a Feb. 7 statement, PriceRunner cited the European General Court’s decision that Alphabet-owned Google had violated the EU’s antitrust laws by manipulating search results to benefit its comparison shopping solution. As such, Google took away from the revenue of comparison shopping services such as PriceRunner and harmed the interests of European customers who ended up overpaying while shopping online.
“This is also a matter of survival for many European entrepreneurial companies and job opportunities within tech. If American tech giants, through a market position almost equal to a monopoly, are allowed to do exactly as they please and manipulate markets, we can almost certainly count on the fact that many tech companies in Europe will be affected far beyond the comparison shopping market in focus today,” Mikael Lindahl, CEO of PriceRunner, said in the statement.
Lindahl said the lawsuit is also a fight for the rights of consumers who have “suffered tremendously” due to Google’s violation of competition law for the past 14 years.
In the statement, PriceRunner noted that Google’s search engine has a market share of 90 percent in most European nations, thereby giving the tech giant a “monopoly-like” position.
In 2017, the European Commission found that the unfair advantage enjoyed by Google’s comparison shopping service on the company’s search engine had deprived European companies of competing on equal grounds. Google was consequently ordered to pay 2.4 billion euros ($2.74 billion). The General Court of the EU upheld the decision in November 2021.
“The General Court finds that, by favoring its own comparison shopping service on its general results pages through more favorable display and positioning, while relegating the results from competing comparison services in those pages by means of ranking algorithms, Google departed from competition on the merits,” the court stated (pdf).
PriceRunner is accusing Google of not complying with the European Commission’s order. As a result, internet traffic is diverted away from PriceRunner and other comparison shopping services.
The company cited research conducted by accountancy firm Grant Thornton to claim that prices shown in Google’s comparison shopping service tend to be 12 percent to 14 percent higher when compared to other similar services. When it comes to items such as clothes and shoes, the price variation goes up to 37 percent. This results in European consumers paying extra amounts to the tune of billions of dollars per year, according to the research.
The lawsuit aims to make Google pay for profits that PriceRunner lost in the UK market from 2008 and from Denmark and Sweden markets from 2013. Such damages are calculated to be 2.1 billion euros up until 2020.
During the court of litigation, the amount of damages mentioned in the lawsuit “will be increased significantly,” as Google’s violation is still ongoing, PriceRunner stated.
Google representatives didn’t reply to a request for comment by press time.
For over 10 years??????????????
Ericsson joins the patent infringement fray against Apple:
Ericsson Sues Apple Over Patent Infringement -- Update
January 18 2022 - 01:12PM
Dow Jones News
By Dominic Chopping
STOCKHOLM--Ericsson AB has filed a number of patent-infringement lawsuits against Apple Inc. for using its technology in products such as its iPhones without a license.
Fallouts in the telecom industry aren't uncommon, as so much technology is shared in communication equipment, and these most recent lawsuits, filed Monday, are the latest in a line of spats between the companies as they argue over royalty payments.
With the rapid development of all-new technology to power 5G and the huge costs involved, developers are keen to ensure they recoup costs via royalties when their technology is used by others.
Apple first licensed Ericsson's patents in 2008 when it released the first iPhone. When that deal expired, a 2015 complaint by Ericsson against Apple led to another global cross-license deal between the companies, but those licenses have now expired after talks to renew the deal at the end of 2021 failed.
In October, Ericsson sued Apple, seeking a declaration that the 5G licensing rate it offered Apple was fair, reasonable and non-discriminatory, noting that the rate of between $2.50 and $5.00 for each 5G handset sold was set in 2017 to offer licensees transparency and predictability.
Apple counter sued in December, claiming the Swedish company was using "strong-arm tactics" to renew patents.
"Ericsson has filed a number of lawsuits against Apple for patent infringement in multiple jurisdictions," Ericsson said in an emailed statement Tuesday. "Since the prior agreement has expired, and we have been unable to reach agreement on the terms and scope of a new license, Apple is now using our technology without a license."
Ericsson spends around $5 billion on research and development every year and has been granted more than 57,000 patents world-wide. Its technology is licensed through more than 100 licensing agreements, which currently generate around 7 billion Swedish kronor ($776.5 million) of annualized revenues.
"We've always been willing to pay a fair price for technology used in our products," Apple told The Wall Street Journal. "Ericsson has refused to negotiate fair terms for renewing our patent licensing agreement, and instead has been suing Apple around the world to extort excessive royalties."
Apple added that it is now asking the court to help determine a fair price for the standard essential patents that would apply worldwide.
"We will continue to defend against their tactics," Apple said.
Me, too....
My favorite race horse's name is "Hoof Hearted"
JJ,
I've got my $3.00 limit order ready to get filled if NLST drops that far.
MJ
60 Minutes on right now doing a piece on the microchip shortage
Elite Announces Co-Development of Four Additional Products with SunGen Pharma
NORTHVALE, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced Elite and SunGen Pharma, LLC ("SunGen") will co-develop four additional generic products bringing the total number of products developed under the amended agreement to eight.
Under the terms of Amendments to the parties' 2016 Development and License Agreement (the "Agreement"), Elite and SunGen will share the responsibilities and costs of development. Three products will be owned jointly by Elite and SunGen; three shall be owned by SunGen while Elite shall have the marketing rights once the products are approved by the FDA; and two shall be owned by Elite while SunGen shall have the marketing rights once the products are approved by the FDA. Elite will manufacture and package all eight products on a cost plus basis.
The product classes for the additional four products include antidepressants, antibiotics, and antispasmodics. The additional four products and their generic equivalents had total U.S. sales of more than $1.4 billion in 2016 according to IMS Health Data. The original four products and their generic equivalents had total U.S. sales of more than $3 billion in 2016 according to IMS Health Data.
Building on the success of the original agreement, Elite announced earlier this month a second agreement signed on July 6, 2017, in which Elite and SunGen will collaborate, develop and commercialize generic pharmaceutical products based upon a unique drug delivery platform used for extended release products. The parties will commence development of five generic extended release products and thereafter develop additional such products as there are more than a dozen products utilizing this type of technology. For the twelve months ending March 31, 2017, the initial five products and their generic equivalents had total U.S. sales of more than $2.5 billion according to IMS Health Data.
"We are delighted to continue building on our great partnership with SunGen, and are looking forward to more collaboration in the near future," said Nasrat Hakim, Chairman and CEO of Elite.
My crystal ball says there's news today at high noon Eastern time....
How about noon tomorrow then, to be technically mid-May?
Technically, it's still mid-May until midnight tonight....
Kermit the Frog was wrong... It's easy being green, Especially, when you're ELTP!
Senderos,
I attended the annual meeting and also had the opportunity to meet/chat with Nasrat. I echo your sentiments about having the utmost confidence in Nasrat's ability to bring success to ELTP.
MJ
Elite offers a solution that prevents the abuse of OxyContin/opioids.
City devastated by OxyContin use sues Purdue Pharma, claims drugmaker put profits over citizens' welfare
Heroin remains an enormous problem in the region, with more than 40 residents fatally overdosing each year and government resources severely taxed. The sole detox center in Snohomish County has only 16 beds, but on any given day the jail might have up to 160 inmates in need of detox, officials said. Everett last year spent $160,000 removing trash from a single city block that has become an open-air drug market. Homelessness has exploded, with addicts living in encampments along highways, behind stores and in wooded areas throughout the city.
Heroin resurgence an 'unintended consequence' of attempt to curb OxyContin abuse, study finds
Heroin resurgence an 'unintended consequence' of attempt to curb OxyContin abuse, study finds
“A lot of individuals we are coming across have worked, have had a job, and somehow they were introduced to prescription drugs,” said Staci McCole, one of two social workers recently embedded with the Everett Police Department to help officers handle addicts.
City lawyers wrote in their suit that the heroin crisis “is directly attributable to Purdue’s wrongful and tortious conduct.”
“We believe that the flooding of the city with OxyContin caused the crisis,” said Hil Kaman, Everett’s public health and safety director. “Our capacity to respond has been overwhelmed, and Purdue should pay for the harm they caused.”
Although Everett is the first municipality to sue Purdue solely on the basis of criminal sales of its drug, other jurisdictions trying to recoup costs of the opioid epidemic have raised the issue, along with claims of fraudulent marketing. Two California counties that sued the company in 2014 said that Purdue knowingly profited from criminal dealings of its drug, citing as evidence the company’s Region Zero program, a secret database of more than 1,800 suspect doctors first revealed by The Times. By the company’s own admission, fewer than 10% of those doctors had been reported to law enforcement.
After the newspaper’s July story, the New Hampshire attorney general issued a subpoena for company records related to criminal trafficking in that state. The company has refused to turn over the material and is battling the state in appellate court over its use of outside lawyers.
Federal regulators have cracked down on opioid wholesalers in recent years for facilitating criminal trafficking. McKesson, one of the nation’s largest of these distributors, paid a $150-million fine this week to settle allegations that it had failed to report suspicious orders to authorities.
The Times’ investigation showed that Purdue had more extensive evidence of suspected criminal trafficking nationally than any single distributor. But historically, manufacturers have not been held responsible for preventing the illicit sales of their drugs.
Experts had mixed opinions about Everett’s chances of recovering money. The suit has similarities to litigation against firearm manufacturers by states and cities deluged with gun violence, experts said. Some of those cases succeeded, but many did not.
Richard Ausness, a University of Kentucky law professor who has written about suits against Purdue, said that the evidence in gun cases was often attenuated, such as sales data showing huge weapons sales in areas with small populations and loose gun laws.
“They didn’t have the specific knowledge that Purdue had,” said Ausness. Purdue “knew that clinic was a front for a criminal enterprise and you don’t really see anything that specific in gun litigation.”
University of Florida law professor Lars Noah, who teaches pharmaceutical regulation and public health law, said he was doubtful that a court would accept Everett’s claim that Purdue was liable for the addiction crisis under the public nuisance statute.
“These theories have been tried with other industries that sell consumer goods and courts with rare exceptions have decided it is too much of a stretch,” Noah said, adding that he considered the case “more of a publicity stunt.”
In Everett, those personally affected by illicit use of OxyContin said they were heartened by the city’s suit. Debbie Warfield’s son, Spencer, became addicted to the drug after high school, often buying pills from street dealers. He later switched to heroin.
“You just couldn’t imagine how your son could be shooting up heroin. It was beyond belief,” Warfield said.
Spencer Warfield died of an overdose in 2012. He was 24.
Of Purdue, she said, “I definitely think they need to take some responsibility.”
“Honestly, it makes me want to cry because it is so overdue,” said Lindsey Greinke, a former OxyContin and heroin addict who now runs an Everett nonprofit that helps people afford detox and treatment programs. “I hope something actually comes of it. We need it.”
https://investorshub.advfn.com/secure/post_new.aspx?board_id=15170
Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017
Conference Call Scheduled for Monday, February 13 at 11:30 AM EST
NORTHVALE, N.J., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter of its 2017 fiscal year.
Consolidated revenues for the third quarter of Fiscal 2017 were $2.3 million, a 6% increase on a year-on-year basis. Continued growth of Elite's niche generic product lines drove the revenue increase. In addition, Elite's product development activities continued, with $1.5 million being spent on the development of Elite's pipeline of products during the quarter.
"This was an important quarter for Elite's pipeline," commented Nasrat Hakim, President and CEO of Elite. "We had a positive meeting with the FDA on SequestOx™ that provides Elite a path to resubmission of the NDA. We followed the filing of a Percocet generic the previous quarter with a filing of a Norco generic this quarter. We have made tremendous progress on the SunGen co-development products and are on track to file two of these products in about 12 months from now. We also had a solid quarter for our financials."
About Elite's Abuse Deterrent Technology
ELTP: Elite Pharmaceuticals, Inc. SEC Filing - Quarterly Report (10-Q) February 9, 2017
http://seekingalpha.com/filing/3396079?uprof=45
Patriots win 34-28.
Just like the Patriots, Elite will come from behind and get SequestOx to market.
Spoke too soon... Super Bowl tied up 28 to 28
An excellent example of perpetrating a massive farce would be predicting a 2 cent Elite share price.
"...The FDA will provide minutes of the meeting by the end of January...."
The end of January is January 31st... Not January 20th.
Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo
NORTHVALE, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of Norco (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Norco is a combination medication and is used to help relieve moderate to moderately severe pain. The combination products of hydrocodone and acetaminophen have total annual US sales of approximately $700 million according to IMS Health data.
"Hydrocodone/acetaminophen is a strategic addition to Elite's pain medicine portfolio. This immediate release opioid product is used extensively by doctors today in pain management. The acetaminophen creates irritation if the product is crushed and taken intranasally, thereby potentially providing some intranasal abuse-deterrence according to the FDA," said Nasrat Hakim, President and CEO of Elite. "Elite is committed to developing a diverse range of opioid abuse-deterrent pain products using our proprietary technology and building a foundation of attractive niche generic drugs."